Cargando…

Latent trajectory modelling of pulmonary artery pressure in systemic sclerosis: a retrospective cohort study

OBJECTIVES: To visualise the trajectories of pulmonary arterial pressure (PAP) in systemic sclerosis (SSc) and identify the clinical phenotypes for each trajectory, by applying latent trajectory modelling for PAP repeatedly estimated by echocardiography. METHODS: This was a multicentre, retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kida, Takashi, Matsuzaki, Keiichi, Yokota, Isao, Kawase, Nozomu, Kadoya, Masatoshi, Inoue, Hironori, Kukida, Yuji, Kaneshita, Shunya, Inoue, Takuya, Wada, Makoto, Kohno, Masataka, Fukuda, Wataru, Kawahito, Yutaka, Iwami, Taku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Systemic Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806097/ https://www.ncbi.nlm.nih.gov/pubmed/36581382 http://dx.doi.org/10.1136/rmdopen-2022-002673

Ejemplares similares

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
por: Kuwana, Masataka, et al.
Publicado: (2020)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
por: Khanna, Dinesh, et al.
Publicado: (2020)

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
por: Kuster, Simon, et al.
Publicado: (2022)

Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2016)

Failed Degradation of JunB Contributes to Overproduction of Type I Collagen and Development of Dermal Fibrosis in Patients With Systemic Sclerosis
por: Ponticos, Markella, et al.
Publicado: (2015)

Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?
por: Hughes, M., et al.
Publicado: (2016)

Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study
por: Cutolo, Maurizio, et al.
Publicado: (2016)

Haematopoietic stem cell transplantation in systemic sclerosis
por: Walker, Ulrich A, et al.
Publicado: (2018)

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo‐Controlled, Phase II Study
por: Denton, Christopher P., et al.
Publicado: (2017)

Molecular Basis for Dysregulated Activation of NKX2‐5 in the Vascular Remodeling of Systemic Sclerosis
por: Dritsoula, Athina, et al.
Publicado: (2018)

A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis–Related Raynaud's Phenomenon
por: Wilkinson, Jack D., et al.
Publicado: (2018)

Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis
por: Ariani, Alarico, et al.
Publicado: (2019)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

Systemic sclerosis: state of the art on clinical practice guidelines
por: Smith, Vanessa, et al.
Publicado: (2018)

Rituximab in early systemic sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2017)

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2019)

Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients
por: Beretta, Lorenzo, et al.
Publicado: (2020)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
por: Spiera, Robert, et al.
Publicado: (2020)

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
por: Allanore, Yannick, et al.
Publicado: (2020)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis
por: Mor, Adi, et al.
Publicado: (2019)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis
por: Carvalheiro, Tiago, et al.
Publicado: (2019)

Spontaneous Pulmonary Hypertension Associated With Systemic Sclerosis in P‐Selectin Glycoprotein Ligand 1–Deficient Mice
por: González‐Tajuelo, Rafael, et al.
Publicado: (2020)

Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis
por: Martin, Mickaël, et al.
Publicado: (2019)

Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH
por: Wasson, Christopher W, et al.
Publicado: (2020)

Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Maher, Toby M., et al.
Publicado: (2021)

Anti-centromere antibodies target centromere–kinetochore macrocomplex: a comprehensive autoantigen profiling
por: Kajio, Nobuhiko, et al.
Publicado: (2021)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Association of Anti–Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic Sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2020)

Patient and healthcare professional eHealth literacy and needs for systemic sclerosis support: a mixed methods study
por: Kocher, Agnes, et al.
Publicado: (2021)

Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers
por: Dumitru, Raluca B, et al.
Publicado: (2021)

Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma
por: Ross, Rebecca L, et al.
Publicado: (2021)

Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature
por: van Leeuwen, Nina M., et al.
Publicado: (2021)

Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries
por: Khanna, Dinesh, et al.
Publicado: (2021)

Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes
por: Acosta-Herrera, Marialbert, et al.
Publicado: (2021)

New risk model is able to identify patients with a low risk of progression in systemic sclerosis
por: van Leeuwen, Nina Marijn, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_odklqgsvsg2at8d6dbhjd9b7uq